5 Drugs Stocks Pushing Industry Growth

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 46 points (-0.3%) at 14,513 as of Wednesday, March 27, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,149 issues advancing vs. 1,749 declining with 144 unchanged.

The Drugs industry currently sits down 0.3% versus the S&P 500, which is down 0.2%. A company within the industry that increased today was AstraZeneca ( AZN), up 0.5%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.33 (0.7%) to $46.33 on heavy volume Thus far, 2.0 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $45.79-$46.36 after having opened the day at $45.86 as compared to the previous trading day's close of $46.00.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $125.1 billion and is part of the health care sector. The company has a P/E ratio of 14.0, below the S&P 500 P/E ratio of 17.7. Shares are up 5.8% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Biogen Idec ( BIIB) is up $2.52 (1.4%) to $179.61 on light volume Thus far, 538,879 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $176.01-$179.64 after having opened the day at $176.52 as compared to the previous trading day's close of $177.09.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $41.6 billion and is part of the health care sector. The company has a P/E ratio of 30.6, above the S&P 500 P/E ratio of 17.7. Shares are up 21.0% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Gilead ( GILD) is up $1.23 (2.7%) to $46.99 on average volume Thus far, 6.7 million shares of Gilead exchanged hands as compared to its average daily volume of 9.3 million shares. The stock has ranged in price between $45.92-$47.09 after having opened the day at $46.20 as compared to the previous trading day's close of $45.76.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $68.5 billion and is part of the health care sector. The company has a P/E ratio of 27.4, above the S&P 500 P/E ratio of 17.7. Shares are up 24.6% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Celgene Corporation ( CELG) is up $0.69 (0.6%) to $113.16 on light volume Thus far, 1.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.8 million shares. The stock has ranged in price between $111.25-$113.20 after having opened the day at $111.52 as compared to the previous trading day's close of $112.47.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $46.8 billion and is part of the health care sector. The company has a P/E ratio of 33.9, above the S&P 500 P/E ratio of 17.7. Shares are up 43.3% year to date as of the close of trading on Tuesday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Amgen ( AMGN) is up $1.09 (1.1%) to $99.75 on light volume Thus far, 1.4 million shares of Amgen exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $98.02-$99.78 after having opened the day at $98.06 as compared to the previous trading day's close of $98.66.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $72.5 billion and is part of the health care sector. The company has a P/E ratio of 17.5, below the S&P 500 P/E ratio of 17.7. Shares are up 14.5% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade

European, Wall Street Futures Slip; Dollar Dips as Trump Hits China on Trade